COMPANIESNEPHRON PHARMACEUTICALS CORPORATION
✓ Verified H1B Sponsor

NEPHRON PHARMACEUTICALS CORPORATION

West Columbia, SCEIN 453731316
TRUST SCORE
74.7
Medium Trust
4
FY2024 H1B Approvals
5
All-time Approvals
74.7
Trust Score / 100

TOP SPONSORED JOB CATEGORIES

Purchasing Agents, Except Wholesale, Retail, and Farm ProductsAccountants and AuditorsEnvironmental Engineers

RECENT H1B FILINGS

JOB TITLELOCATIONWAGEDATE
Environmental EngineersWest Columbia, SC$52,000Oct 2025
MicrobiologistsWest Columbia, SC$54,080Oct 2025
Quality Control Systems ManagersWest Columbia, SC$130,000Oct 2025
Purchasing Agents, Except Wholesale, Retail, and Farm ProductsWest Columbia, SC$50,000Oct 2024
Purchasing Agents, Except Wholesale, Retail, and Farm ProductsWest Columbia, SC$50,000Oct 2024
Accountants and AuditorsWest Columbia, SC$75,000May 2024

SHOWING 50 MOST RECENT · SOURCE: DOL LCA PUBLIC DATA FY2024 · EIN 453731316

FREQUENTLY ASKED QUESTIONS

Does NEPHRON PHARMACEUTICALS CORPORATION sponsor H1B visas?

Yes. NEPHRON PHARMACEUTICALS CORPORATION has an active H1B sponsorship history with 5 total approved LCA filings on record, including 4 approvals in FY2024. Data sourced from US Department of Labor public disclosure files.

How many H1B visas has NEPHRON PHARMACEUTICALS CORPORATION sponsored?

According to DOL LCA data, NEPHRON PHARMACEUTICALS CORPORATION has 5 all-time H1B approvals and 4 approvals in fiscal year 2024.

What types of roles does NEPHRON PHARMACEUTICALS CORPORATION sponsor H1B for?

NEPHRON PHARMACEUTICALS CORPORATION most commonly sponsors H1B visas for: Purchasing Agents, Except Wholesale, Retail, and Farm Products, Accountants and Auditors, Environmental Engineers. This is based on their DOL Labor Condition Application filing history.

Is NEPHRON PHARMACEUTICALS CORPORATION a reliable H1B sponsor?

NEPHRON PHARMACEUTICALS CORPORATION has a Trust Score of 74.7/100 on KEEL, calculated from total approval volume, recency of filings, and approval consistency based on DOL LCA data.

DATA SOURCE: US DEPT. OF LABOR · LCA PUBLIC DISCLOSURE FY2023–FY2024